Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 587

1.

Sorting Signed Permutations by Inverse Tandem Duplication Random Losses.

Hartmann T, Bannach M, Middendorf M.

IEEE/ACM Trans Comput Biol Bioinform. 2019 May 16. doi: 10.1109/TCBB.2019.2917198. [Epub ahead of print]

PMID:
31095495
2.

Evolving Images for Visual Neurons Using a Deep Generative Network Reveals Coding Principles and Neuronal Preferences.

Ponce CR, Xiao W, Schade PF, Hartmann TS, Kreiman G, Livingstone MS.

Cell. 2019 May 2;177(4):999-1009.e10. doi: 10.1016/j.cell.2019.04.005.

PMID:
31051108
3.

Pushing data quality for laboratory pair distribution function experiments.

Thomae SLJ, Prinz N, Hartmann T, Teck M, Correll S, Zobel M.

Rev Sci Instrum. 2019 Apr;90(4):043905. doi: 10.1063/1.5093714.

PMID:
31043011
4.

Profiling of Alzheimer's disease related genes in mild to moderate vitamin D hypovitaminosis.

Grimm MOW, Lauer AA, Grösgen S, Thiel A, Lehmann J, Winkler J, Janitschke D, Herr C, Beisswenger C, Bals R, Grimm HS, Hartmann T.

J Nutr Biochem. 2019 May;67:123-137. doi: 10.1016/j.jnutbio.2019.01.015. Epub 2019 Feb 11.

PMID:
30889441
5.

Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease.

Reinhardt S, Schuck F, Stoye N, Hartmann T, Grimm MOW, Pflugfelder G, Endres K.

Cell Mol Life Sci. 2019 Mar;76(5):1005-1025. doi: 10.1007/s00018-018-2998-2. Epub 2019 Jan 1.

PMID:
30599067
6.

Rac GTPases in Hematological Malignancies.

Durand-Onaylı V, Haslauer T, Härzschel A, Hartmann TN.

Int J Mol Sci. 2018 Dec 14;19(12). pii: E4041. doi: 10.3390/ijms19124041. Review.

7.

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Asslaber D, Wacht N, Leisch M, Qi Y, Maeding N, Hufnagl C, Jansko B, Zaborsky N, Villunger A, Hartmann TN, Greil R, Egle A.

Clin Cancer Res. 2019 Mar 15;25(6):1901-1912. doi: 10.1158/1078-0432.CCR-18-1548. Epub 2018 Nov 28.

PMID:
30487125
8.

Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications.

Zucchetto A, Tissino E, Chigaev A, Hartmann TN, Gattei V.

Methods Mol Biol. 2019;1881:101-112. doi: 10.1007/978-1-4939-8876-1_8.

PMID:
30350200
9.

Paradoxical effects of mutant ubiquitin on Aβ plaque formation in an Alzheimer mouse model.

Verheijen BM, Stevens JAA, Gentier RJG, van 't Hekke CD, van den Hove DLA, Hermes DJHP, Steinbusch HWM, Ruijter JM, Grimm MOW, Haupenthal VJ, Annaert W, Hartmann T, van Leeuwen FW.

Neurobiol Aging. 2018 Dec;72:62-71. doi: 10.1016/j.neurobiolaging.2018.08.011. Epub 2018 Aug 18.

10.

Remission maintenance treatment options in chronic lymphocytic leukemia.

Egle A, Pleyer L, Melchardt T, Hartmann TN, Greil R.

Cancer Treat Rev. 2018 Nov;70:56-66. doi: 10.1016/j.ctrv.2018.08.003. Epub 2018 Aug 10. Review.

PMID:
30121491
11.

An Exact Algorithm for Sorting by Weighted Preserving Genome Rearrangements.

Hartmann T, Bernt M, Middendorf M.

IEEE/ACM Trans Comput Biol Bioinform. 2019 Jan-Feb;16(1):52-62. doi: 10.1109/TCBB.2018.2831661. Epub 2018 Apr 30.

PMID:
29994030
12.

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Sep;97(9):1745. doi: 10.1007/s00277-018-3403-9.

PMID:
29934835
13.

Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion.

Barbero-Camps E, Roca-Agujetas V, Bartolessis I, de Dios C, Fernández-Checa JC, Marí M, Morales A, Hartmann T, Colell A.

Autophagy. 2018;14(7):1129-1154. doi: 10.1080/15548627.2018.1438807. Epub 2018 Jun 4.

14.

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Oct;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z. Epub 2018 Jun 4. Erratum in: Ann Hematol. 2018 Jun 23;:.

15.

EqualTDRL: illustrating equivalent tandem duplication random loss rearrangements.

Hartmann T, Bernt M, Middendorf M.

BMC Bioinformatics. 2018 May 30;19(1):192. doi: 10.1186/s12859-018-2170-x.

16.

[Which medications are safe while breastfeeding? : A synopsis for the anesthetist, obstetrician and pediatrician].

Fischer A, Ortner C, Hartmann T, Jochberger S, Klein KU.

Wien Med Wochenschr. 2019 Mar;169(3-4):45-55. doi: 10.1007/s10354-018-0637-z. Epub 2018 Apr 24. Review. German.

PMID:
29691694
17.

Travelling without a helmet: tourists' vulnerabilities and responses to disasters in Indonesia.

Rindrasih E, Hartmann T, Witte P, Spit T, Zoomers A.

Disasters. 2018 Oct;42(4):782-803. doi: 10.1111/disa.12281. Epub 2018 Mar 13.

PMID:
29532949
18.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Melchardt T, Magnes T, Hufnagl C, Thorner AR, Ducar M, Neureiter D, Tränkenschuh W, Klieser E, Gaggl A, Rösch S, Rasp G, Hartmann TN, Pleyer L, Rinnerthaler G, Weiss L, Greil R, Egle A.

Eur J Cancer. 2018 Apr;93:69-78. doi: 10.1016/j.ejca.2018.01.064. Epub 2018 Mar 20.

PMID:
29477794
19.

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.

Gutjahr JC, Szenes E, Tschech L, Asslaber D, Schlederer M, Roos S, Yu X, Girbl T, Sternberg C, Egle A, Aberger F, Alon R, Kenner L, Greil R, Orian-Rousseau V, Hartmann TN.

Blood. 2018 Mar 22;131(12):1337-1349. doi: 10.1182/blood-2017-08-802462. Epub 2018 Jan 19.

20.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

Supplemental Content

Loading ...
Support Center